<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/355c" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/355c/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/355c/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_355c"><akn:num>355c</akn:num><akn:heading>Research into pediatric uses for drugs and biological products</akn:heading><akn:content><akn:p>§ 355c. Research into pediatric uses for drugs and biological products(a) New drugs and biological products(1) In general(A) General requirementsExcept with respect to an application for which subparagraph (B) applies, a person that submits, on or after September 27, 2007, an application (or supplement to an application) for a drug—(i) under section 355 of this title for a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration; or

(ii) under section 262 of title 42 for a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration,


shall submit with the application the assessments described in paragraph (2).

(B) Certain molecularly targeted cancer indicationsA person that submits, on or after the date that is 3 years after August 18, 2017, an original application for a new active ingredient under section 355 of this title or section 262 of title 42, shall submit with the application reports on the investigation described in paragraph (3) if the drug or biological product that is the subject of the application is—(i) intended for the treatment of an adult cancer; and

(ii) directed at a molecular target that the Secretary determines to be substantially relevant to the growth or progression of a pediatric cancer.



(2) Assessments(A) In generalThe assessments referred to in paragraph (1)(A) shall contain data, gathered using appropriate formulations for each age group for which the assessment is required, that are adequate—(i) to assess the safety and effectiveness of the drug or the biological product for the claimed indications in all relevant pediatric subpopulations; and

(ii) to support dosing and administration for each pediatric subpopulation for which the drug or the biological product is safe and effective.


(B) Similar course of disease or similar effect of drug or biological product(i) In generalIf the course of the disease and the effects of the drug are</akn:p></akn:content><akn:subsection eId="subsec_355c_a"><akn:num>(a)</akn:num><akn:heading>New drugs and biological products</akn:heading><akn:content><akn:p>(a) New drugs and biological products</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355c_b"><akn:num>(b)</akn:num><akn:heading>Marketed drugs and biological products</akn:heading><akn:content><akn:p>(b) Marketed drugs and biological products</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355c_c"><akn:num>(c)</akn:num><akn:heading>Meaningful therapeutic benefit</akn:heading><akn:content><akn:p>(c) Meaningful therapeutic benefit For the purposes of paragraph (4)(A)(iii)(I) and (4)(B)(iii)(I) of subsection (a) and paragraphs (1)(B) and (2)(B)(iii)(I)(aa) of subsection (b), a drug or biological product shall be considered to represent a meaningful therapeutic benefit over existing therapies if the Secretary determines that—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355c_d"><akn:num>(d)</akn:num><akn:heading>Submission of assessments and reports on the investigation</akn:heading><akn:content><akn:p>(d) Submission of assessments and reports on the investigation If a person fails to submit a required assessment described in subsection (a)(2) or the investigation described in subsection (a)(3), fails to meet the applicable requirements in subsection (a)(4), or fails to submit a request for approval of a pediatric formulation described in subsection (a) or (b), in accordance with applicable provisions of subsections (a) and (b), the following shall apply:</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355c_e"><akn:num>(e)</akn:num><akn:heading>Pediatric study plans</akn:heading><akn:content><akn:p>(e) Pediatric study plans</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355c_f"><akn:num>(f)</akn:num><akn:heading>Review of pediatric study plans, assessments, deferrals, deferral extensions, and waivers</akn:heading><akn:content><akn:p>(f) Review of pediatric study plans, assessments, deferrals, deferral extensions, and waivers</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355c_g"><akn:num>(g)</akn:num><akn:heading>Labeling changes</akn:heading><akn:content><akn:p>(g) Labeling changes</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355c_h"><akn:num>(h)</akn:num><akn:heading>Dissemination of pediatric information</akn:heading><akn:content><akn:p>(h) Dissemination of pediatric information</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355c_i"><akn:num>(i)</akn:num><akn:heading>Adverse event reporting</akn:heading><akn:content><akn:p>(i) Adverse event reporting</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355c_j"><akn:num>(j)</akn:num><akn:heading>Scope of authority</akn:heading><akn:content><akn:p>(j) Scope of authority Nothing in this section provides to the Secretary any authority to require a pediatric assessment of any drug or biological product, or any assessment regarding other populations or uses of a drug or biological product, other than the pediatric assessments described in this section.</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>